Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation

Luigi Di Biase; David Callans; Karl Georg Haeusler; Gerhard Hindricks; Hussein Al-Khalidi; Lluis Mont; Jens Cosedis Nielsen; Jonathan P. Piccini; Ulrich Schotten; Paulus Kirchhof

doi:10.1093/europace/euw368

Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation

Luigi Di Biase, David Callans, Karl Georg Haeusler, Gerhard Hindricks, Hussein Al-Khalidi, Lluis Mont, Jens Cosedis Nielsen, Jonathan P. Piccini, Ulrich Schotten, Paulus Kirchhof^*

^*Corresponding author for this work

Fysiologie

Research output: Contribution to journal › Article › Academic › peer-review

24 Citations (Web of Science)

Original language	English
Pages (from-to)	132-138
Number of pages	7
Journal	EP Europace
Volume	19
Issue number	1
DOIs	https://doi.org/10.1093/europace/euw368
Publication status	Published - Jan 2017

Keywords

Atrial fibrillation
Ablation
Oral anticoagulation
Apixaban
Warfarin
Un-interrupted
Stroke
Bleeding
ACADEMIC RESEARCH CONSORTIUM
PERIPROCEDURAL ANTICOAGULATION
RADIOFREQUENCY ABLATION
BLEEDING COMPLICATIONS
UNINTERRUPTED RIVAROXABAN
MEDICARE BENEFICIARIES
ORAL ANTICOAGULANTS
SAFETY
DABIGATRAN
MANAGEMENT

Access to Document

10.1093/europace/euw368

Cite this

Di Biase, L., Callans, D., Haeusler, K. G., Hindricks, G., Al-Khalidi, H., Mont, L., Nielsen, J. C., Piccini, J. P., Schotten, U., & Kirchhof, P. (2017). Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. EP Europace, 19(1), 132-138. https://doi.org/10.1093/europace/euw368

Di Biase, Luigi ; Callans, David ; Haeusler, Karl Georg ; Hindricks, Gerhard ; Al-Khalidi, Hussein ; Mont, Lluis ; Nielsen, Jens Cosedis ; Piccini, Jonathan P. ; Schotten, Ulrich ; Kirchhof, Paulus. / Rationale and design of AXAFA-AFNET 5 : an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. In: EP Europace. 2017 ; Vol. 19, No. 1. pp. 132-138.

@article{943b879c14c240a19ca268ec4a7be59d,

title = "Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation",

keywords = "Atrial fibrillation, Ablation, Oral anticoagulation, Apixaban, Warfarin, Un-interrupted, Stroke, Bleeding, ACADEMIC RESEARCH CONSORTIUM, PERIPROCEDURAL ANTICOAGULATION, RADIOFREQUENCY ABLATION, BLEEDING COMPLICATIONS, UNINTERRUPTED RIVAROXABAN, MEDICARE BENEFICIARIES, ORAL ANTICOAGULANTS, SAFETY, DABIGATRAN, MANAGEMENT",

author = "{Di Biase}, Luigi and David Callans and Haeusler, {Karl Georg} and Gerhard Hindricks and Hussein Al-Khalidi and Lluis Mont and Nielsen, {Jens Cosedis} and Piccini, {Jonathan P.} and Ulrich Schotten and Paulus Kirchhof",

year = "2017",

month = jan,

doi = "10.1093/europace/euw368",

language = "English",

volume = "19",

pages = "132--138",

journal = "EP Europace",

issn = "1099-5129",

publisher = "Oxford University Press",

number = "1",

}

Di Biase, L, Callans, D, Haeusler, KG, Hindricks, G, Al-Khalidi, H, Mont, L, Nielsen, JC, Piccini, JP, Schotten, U & Kirchhof, P 2017, 'Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation', EP Europace, vol. 19, no. 1, pp. 132-138. https://doi.org/10.1093/europace/euw368

Rationale and design of AXAFA-AFNET 5 : an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. / Di Biase, Luigi; Callans, David; Haeusler, Karl Georg; Hindricks, Gerhard; Al-Khalidi, Hussein; Mont, Lluis; Nielsen, Jens Cosedis; Piccini, Jonathan P.; Schotten, Ulrich; Kirchhof, Paulus.

In: EP Europace, Vol. 19, No. 1, 01.2017, p. 132-138.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rationale and design of AXAFA-AFNET 5

T2 - an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation

AU - Di Biase, Luigi

AU - Callans, David

AU - Haeusler, Karl Georg

AU - Hindricks, Gerhard

AU - Al-Khalidi, Hussein

AU - Mont, Lluis

AU - Nielsen, Jens Cosedis

AU - Piccini, Jonathan P.

AU - Schotten, Ulrich

AU - Kirchhof, Paulus

PY - 2017/1

Y1 - 2017/1

KW - Atrial fibrillation

KW - Ablation

KW - Oral anticoagulation

KW - Apixaban

KW - Warfarin

KW - Un-interrupted

KW - Stroke

KW - Bleeding

KW - ACADEMIC RESEARCH CONSORTIUM

KW - PERIPROCEDURAL ANTICOAGULATION

KW - RADIOFREQUENCY ABLATION

KW - BLEEDING COMPLICATIONS

KW - UNINTERRUPTED RIVAROXABAN

KW - MEDICARE BENEFICIARIES

KW - ORAL ANTICOAGULANTS

KW - SAFETY

KW - DABIGATRAN

KW - MANAGEMENT

U2 - 10.1093/europace/euw368

DO - 10.1093/europace/euw368

M3 - Article

C2 - 28130378

VL - 19

SP - 132

EP - 138

JO - EP Europace

JF - EP Europace

SN - 1099-5129

IS - 1

ER -

Di Biase L, Callans D, Haeusler KG, Hindricks G, Al-Khalidi H, Mont L et al. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. EP Europace. 2017 Jan;19(1):132-138. https://doi.org/10.1093/europace/euw368